Navigation Links
Enrollment for Medicare IVIG Demonstration Project Begins August 8, 2014
Date:8/6/2014

medically appropriate."

The demonstration project should prove the cost effectiveness of allowing Medicare patients with PI access to home infusions of IVIG, thus paving the way for a permanent fix to this issue.

For more information, or to get a copy of the enrollment application, visit http://www.medicarenhic.com, or call (844)-625-6284. Please note that submitting an application for this demonstration does not guarantee that a patient will be selected to participate.


'/>"/>
SOURCE Immune Deficiency Foundation
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Generex Announces Completion of Enrollment of Antigen Express Phase II AE37 Breast Cancer Vaccine Trial
2. Verified Clinical Trials Stops Dual Enrollment in Clinical Trials in Major CNS Clinical Trials to Reduce Potential Adverse Events and Improve Data Quality
3. Major CRO Gives Top Ratings To Verified Clinical Trials To Stop Dual Enrollment In Clinical Trials On Late Phase Trial
4. AtheroNova Completes Enrollment in Phase 1 Clinical Trial of AHRO-001, a Potential Treatment for Atherosclerosis
5. Verified Clinical Trials Selected to Prevent Dual Enrollment in Clinical Trials, Will Add Over 800 Additional Sites for a New Phase 3 North American Clinical Trial
6. TrialNetworks Customer to Present Results of Using Site Engagement Technology to Improve Study Operations and Patient Enrollment at Clinical Trial Optimization Conference
7. Study Scavenger and CenterWatch Partner to Improve Patient Recruitment, Enrollment and Mobile Access to Clinical Trials with New Study Scavenger Smartphone App
8. Ohr Pharmaceutical Achieves 50% Enrollment Milestone in Squalamine Eye Drop Phase II Clinical Trial
9. Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis
10. Spaulding Clinical Research Partners With Verified Clinical Trials Protecting Clinical Trials From Dual Enrollment
11. NeuroDerm Announces Enrollment in a Phase 2 Study of ND0612, a Continuous Levodopa/Carbidopa Drug for the Treatment of Parkinsons Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... 3, 2015  StemProtein LLC, a leading manufacturer ... of Stemedica Cell Technologies Inc., announced today that ... CEO of StemProtein. Silberg will help advance the ... Stem Cell Factors (SCFs), a significant consumer opportunity. ... pharmaceutical and biopharmaceutical industries with substantial executive level ...
(Date:9/2/2015)... Axovant Sciences Ltd. (NYSE:  AXON), a leading clinical-stage biopharmaceutical company ... at three investor conferences: , Wednesday, September 9 ... New York at the New York ... at the BioCentury NewsMakers Conference in New York ... , Thursday, September 17 at 9:30 AM at the ...
(Date:9/2/2015)... ... 2015 , ... The wet form of macular degeneration, although ... growth factor agents given by injection into the eye. Dry macular degeneration (AMD) ... for the many millions diagnosed with it. AMD usually starts in older age ...
(Date:9/2/2015)... Mass. (PRWEB) , ... September 02, 2015 , ... ... includes development of botanical and plant-derived compounds. BCC Research reveals in its ... past 2020 because this market defines the category and generates the most market ...
Breaking Biology Technology:StemProtein Names Thomas H. Silberg As CEO, To Focus On Stem Cell Secreted Proteins Addresing A Variety Of Health And Beauty Related Needs 2StemProtein Names Thomas H. Silberg As CEO, To Focus On Stem Cell Secreted Proteins Addresing A Variety Of Health And Beauty Related Needs 3Axovant Sciences To Present At Upcoming Investor Conferences 2Axovant Sciences To Present At Upcoming Investor Conferences 3StemCell GeneticMed Announces That It Has Started Stem Cell Treatments for Age Related Dry Macular Degeneration (AMG) 2Plant-derived Compounds Poised to Assume Greater Role in Global Drug Markets, According to BCC Research 2Plant-derived Compounds Poised to Assume Greater Role in Global Drug Markets, According to BCC Research 3
... ... Akt/mTOR inhibitor -, JAMAICA ... has presented three presentations at the 2008,annual meeting of the ... P529 is a non-steroidal, synthetic, small molecule dual acting,anti-angiogenic ...
... DEERFIELD, Ill., April 15 , What and ... CHICAGO (Carotid,intima-media tHICkness in Atherosclerosis using pioGlitazOne) published,today ... thickness (CIMT) with ACTOS(R) (pioglitazone HCl) was,associated with ... when compared to glimepiride., The increased effect ...
... /PRNewswire/ - The acceptance of Peros, oral,delivery platform ... achievement by Benchmark Biolabs, a full service,biopharmaceutical product ... oversees the operation and,management of the Peros production ... biotechnology campus in Lincoln, NE., By obtaining ...
Cached Biology Technology:Paloma Pharmaceuticals to Present at the American Association for Cancer Research 2Paloma Pharmaceuticals to Present at the American Association for Cancer Research 3Paloma Pharmaceuticals to Present at the American Association for Cancer Research 4New Data Published in Circulation Showed an Increase in HDL Cholesterol Levels with ACTOS(R) (pioglitazone HCl) 2New Data Published in Circulation Showed an Increase in HDL Cholesterol Levels with ACTOS(R) (pioglitazone HCl) 3Another industry first enabled by Benchmark Biolabs - Peros' oral delivery platform and vaccine facility licensed by the USDA 2
(Date:8/26/2015)... 2015 The report "Multi-Factor Authentication (MFA) ... Application (Travel & Immigration, Government, Banking, Defense, Commercial Security, ... 2020", published by MarketsandMarkets, Multi-Factor Authentication Market is expected ... a CAGR of 17.7% between 2015 and 2020. ... igures spread through 169 P ages ...
(Date:8/24/2015)... South Africa , August 24, 2015 ... Germany ,s largest biometrics manufacturer DERMALOG and its ... with the "2015 African Biometrics Company of the Year Award". ... Nigeria .   -Cross reference: ... http://www.presseportal.de/nr/8896 - On Thursday evening, in ...
(Date:8/20/2015)... 20, 2015 The wearable technology market ... active and healthy. However, wearable technology has the ... to help improve diagnostic capabilities and therapeutic outcomes. ... Wearable Technologies Conference 2015 , where ... wearables in healthcare.    "Over the ...
Breaking Biology News(10 mins):Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 2Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 3Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 4Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 5Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 2Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 3Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3
... -- Sequella, Inc., a clinical-stage biopharmaceutical company focused ... potential, announced today that the U.S. Food and ... (EMEA) independently reviewed Sequella lead drug compound, SQ109, ... for the treatment of tuberculosis. SQ109 shows excellent ...
... October 22, 2007 (TORONTO) Height may point to ... released by the Centre for Addiction and Mental Health ... on average than males without a sexual attraction to ... A Journal of Research and Treatment, suggests that pedophiles ...
... collaboration, more than 200 medical and scientific journals ... relationship between poverty and human development. The initiative, ... presentations on seven of the journal articles which ... of Health on Monday, October 22, 2007. ...
Cached Biology News:Sequella receives US and EU orphan drug status for SQ109 for the treatment of TB 2Sequella receives US and EU orphan drug status for SQ109 for the treatment of TB 3200 journals join in theme issues on poverty and human development 2200 journals join in theme issues on poverty and human development 3200 journals join in theme issues on poverty and human development 4200 journals join in theme issues on poverty and human development 5
... Dinitro-5,5'-dithiodibenzoic acid , DTNB , Ellman's reagent ... , *CAS-No.: 69-78-3 *Storage: RT, ... a reactive grouping not present in the substrate, ... which will react directly with the product to ...
... enzyme-linked immunosorbent assay (ELISA) test kits ... devices for the detection of drugs and/or ... are intended for forensic use only. It ... confirmed by a quantitative method such as ...
Cag-A (IgG) -Ab EIA Sample Size: 10 l...
... (patent pending) is a protein based inhibitor ... inhibits the most common and troublesome RNases ... T1. SUPERaseIn can be used in any ... It is ideal for in vitro transcription ...
Biology Products: